Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE

By sjmartinez • May 29, 2023

Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE. Br J Haematol. 2023 May 29. doi: 10.1111/bjh.18883. Epub ahead of print. PMID: 37246588.

Tags: chronic phase chronic myeloid leukaemia, dasatinib, deep molecular response, Hematology/Oncology, major molecular response, Publications, treatment-free remission

Diet, nutrition, and hormone therapy for prostate cancer: a systematic review with implications for future interventions

Pahulu I, Calumpit M, Tominez P, Shih JJ, Ebrahimi S, Deville NV, Samoa R, Moin T, Sedrak MS, Valle LF, Steinberg M, Kishan AU, Ganz[...]

Screening for frailty and malnutrition in a multidisciplinary head and neck cancer program

Brauer ER, Lazaro S, Economou DR, Rapkin D, Wong DJ, St John MA. Screening for frailty and malnutrition in a multidisciplinary head and neck cancer[...]

Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy

Nikitas J, Smith CP, Armstrong WR, Murthy V, Grogan T, Clark K, Moore J, Roberts M, Farolfi A, Reiter RE, Rettig MB, Shen J, Valle[...]